NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Genmab A/S (GMAB) Stock Analysis

Genmab A/S (GMAB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

GMAB

$33.60

−$0.81 (−2.35%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GMAB with… →

GMAB Key Statistics

As of Sep 4, 2026
Trading
Open
$33.96
Previous Close
$34.41
Day's Range
33.55–34.19
52-Week Range
23.62–35.43
Volume
1.00M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.70
Valuation
Market Cap
$20.65B
P/E Ratio
27.10
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
21.13
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
5.76
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.00
EPS (ttm)Profit attributable to each share over the last twelve months.
1.24
Financials (FY)
Revenue (FY)
$3.72B+19.19%
Net Income (FY)
$963.00M−15.00%
Profit marginThe share of revenue left as profit after all costs and taxes.
19.07%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
614.62M
1-Year Return
+22.72%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
2.17M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GMAB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+9.09%
2025+47.58%
2024−34.45%
2023−24.87%
2022+7.13%
2021−2.71%
2020+82.09%
2019+35.54%
2018−0.61%
2017−0.04%
2016 (partial year)−9.05%

As of September 4, 2026.

GMAB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$3.72B$963.00M25.9%
2024$3.12B$1.13B36.3%
2023$2.39B$631.00M26.4%
2022$2.09B$784.70M37.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.72B$3.48B$1.25B$963.00M25.9%
2024$3.12B$2.98B$1.02B$1.13B36.3%
2023$2.39B$2.36B$772.00M$631.00M26.4%
2022$2.09B$2.09B$902.00M$784.70M37.6%
2021———$450.16M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GMAB Valuation vs Biotechnology Median

Median of 656 stocks
MetricGMABBiotechnology medianvs median
P/E27.1012.57116% above
P/S ratio5.0015.260.3x the median
Profit margin19.07%0.00%19.1 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Genmab A/S (GMAB) is capitalised at $20.65B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 3,119.

The most recent close on file for GMAB is $33.60, dated September 4, 2026. That is −$0.81 (−2.35%) against the previous close. Over the past 52 weeks the price has ranged from $23.62 to $35.43. The latest close sits 42.25% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $3.72B. Against the prior fiscal year total of $3.12B, that is a change of +19.19%. The same year closed with net income of $963.00M. That is −15.00% against the prior fiscal year. The reported profit margin is 19.08%. That is 19.1 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 1.24.

Of those 5 years, 5 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 27.1. That is 115.59% above the Biotechnology median of 12.57. The forward P/E on file is 21.13. The PEG ratio, which sets the P/E against expected earnings growth, reads 5.76. The price-to-sales ratio is 5. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +22.72%. Across 10 years the annualized return works out at +7.79%. The reported beta is 0.7. Annualized volatility over the trailing 10 years is 34.9%.

Growth & Income

No dividend is on file for GMAB.

So far in 2026 the price is +9.09%. Across the complete calendar years on file, 2020 returned +82.09% and 2024 returned −34.45%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Genmab A/S (GMAB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Genmab A/S GMAB $20.65B 27.1
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Genmab A/S trades at a P/E of 27.1.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Visit website →